Sfoglia per Autore
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.
2013-01-01 Corso S;Giordano S
MicroRNAs: New tools for diagnosis, prognosis and therapy in hepatocellular carcinoma?
2013-01-01 Giordano S;Columbano A
Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells.
2013-01-01 Rapa I;Volante M;Migliore C;Farsetti A;Berruti A;Vittorio Scagliotti G;Giordano S;Papotti M
Resistance to targeted therapies: a role for microRNAs?
2013-01-01 Migliore C;Giordano S
Met as a therapeutic target in HCC: Facts and hopes.
2013-01-01 Giordano S; Columbano A.
Targeting MET: why, where and how?
2013-01-01 Ghiso E;Giordano S
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer.
2012-01-01 Migliore C;Martin V;Leoni VP;Restivo A;Atzori L;Petrelli A;Isella C;Zorcolo L;Sarotto I;Casula G;Comoglio PM;Columbano A;Giordano S
Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway.
2012-01-01 Ancot F;Leroy C;Muharram G;Lefebvre J;Vicogne J;Lemiere A;Kherrouche Z;Foveau B;Pourtier A;Melnyk O;Giordano S;Chotteau-Lelievre A;Tulasne D
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
2012-01-01 Petrelli A;Perra A;Schernhuber K;Cargnelutti M;Salvi A;Migliore C;Ghiso E;Benetti A;Barlati S;Ledda-Columbano GM;Portolani N;De Petro G;Columbano A;Giordano S
I recettori per i fattori di crescita
2012-01-01 S. Giordano; C. Boccaccio; P.M. Comoglio
Fisiopatologia del sangue
2012-01-01 A. Columbano; S. Giordano
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer
2012-01-01 M. Todorovic; S. Corso; L. Gammaitoni; V. Leuci; G. Mesiano; L. Giraudo Diego; S. Capellero; S. Giordano; M. Aglietta; D. Sangiolo
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
2011-01-01 Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F.
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells.
2011-01-01 Comito G;Calvani M;Giannoni E;Bianchini F;Calorini L;Torre E;Migliore C;Giordano S;Chiarugi P
Enhanced c-Met activity promotes G-CSF induced mobilization of hematopoietic progenitor cells via ROS signaling.
2011-01-01 Tesio M; Golan K; Corso S; Giordano S; Schajnovitz A; Vagima Y; Shivtiel S; Kalinkovich A; Caione L; Gammaitoni L; Laurenti E; Buss EC; Shezen E; Itkin T; Kollet O; Petit I; Trumpp A; Christensen J; Aglietta M; Piacibello W; Lapidot T.
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice.
2011-01-01 Kowalik MA;Saliba C;Pibiri M;Perra A;Ledda-Columbano GM;Sarotto I;Ghiso E;Giordano S;Columbano A
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3
2011-01-01 Leoni VP;Ledda-Columbano GM;Pibiri M;Saliba C;Perra A;Kowalik MA;Grober OM;Ravo M;Weisz A;Locker J;Ghiso E;Giordano S;Columbano A
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
2010-01-01 V. Cepero;J. R. Sierra;S. Corso;E. Ghiso;L. Casorzo;T. Perera;P. M. Comoglio;S. Giordano
Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells.
2010-01-01 Todaro M; Iovino F; Eterno V; Cammareri P; Gambara G; Espina V; Gulotta G; Dieli F; Giordano S; De Maria R; Stassi G.
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
2010-01-01 Cepero V; Sierra JR; Giordano S.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. | 2013 | Corso S;Giordano S | |
MicroRNAs: New tools for diagnosis, prognosis and therapy in hepatocellular carcinoma? | 2013 | Giordano S;Columbano A | |
Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. | 2013 | Rapa I;Volante M;Migliore C;Farsetti A;Berruti A;Vittorio Scagliotti G;Giordano S;Papotti M | |
Resistance to targeted therapies: a role for microRNAs? | 2013 | Migliore C;Giordano S | |
Met as a therapeutic target in HCC: Facts and hopes. | 2013 | Giordano S; Columbano A. | |
Targeting MET: why, where and how? | 2013 | Ghiso E;Giordano S | |
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer. | 2012 | Migliore C;Martin V;Leoni VP;Restivo A;Atzori L;Petrelli A;Isella C;Zorcolo L;Sarotto I;Casula G;Comoglio PM;Columbano A;Giordano S | |
Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. | 2012 | Ancot F;Leroy C;Muharram G;Lefebvre J;Vicogne J;Lemiere A;Kherrouche Z;Foveau B;Pourtier A;Melnyk O;Giordano S;Chotteau-Lelievre A;Tulasne D | |
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. | 2012 | Petrelli A;Perra A;Schernhuber K;Cargnelutti M;Salvi A;Migliore C;Ghiso E;Benetti A;Barlati S;Ledda-Columbano GM;Portolani N;De Petro G;Columbano A;Giordano S | |
I recettori per i fattori di crescita | 2012 | S. Giordano; C. Boccaccio; P.M. Comoglio | |
Fisiopatologia del sangue | 2012 | A. Columbano; S. Giordano | |
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer | 2012 | M. Todorovic; S. Corso; L. Gammaitoni; V. Leuci; G. Mesiano; L. Giraudo Diego; S. Capellero; S. Giordano; M. Aglietta; D. Sangiolo | |
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib | 2011 | Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F. | |
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. | 2011 | Comito G;Calvani M;Giannoni E;Bianchini F;Calorini L;Torre E;Migliore C;Giordano S;Chiarugi P | |
Enhanced c-Met activity promotes G-CSF induced mobilization of hematopoietic progenitor cells via ROS signaling. | 2011 | Tesio M; Golan K; Corso S; Giordano S; Schajnovitz A; Vagima Y; Shivtiel S; Kalinkovich A; Caione L; Gammaitoni L; Laurenti E; Buss EC; Shezen E; Itkin T; Kollet O; Petit I; Trumpp A; Christensen J; Aglietta M; Piacibello W; Lapidot T. | |
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. | 2011 | Kowalik MA;Saliba C;Pibiri M;Perra A;Ledda-Columbano GM;Sarotto I;Ghiso E;Giordano S;Columbano A | |
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3 | 2011 | Leoni VP;Ledda-Columbano GM;Pibiri M;Saliba C;Perra A;Kowalik MA;Grober OM;Ravo M;Weisz A;Locker J;Ghiso E;Giordano S;Columbano A | |
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. | 2010 | V. Cepero;J. R. Sierra;S. Corso;E. Ghiso;L. Casorzo;T. Perera;P. M. Comoglio;S. Giordano | |
Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells. | 2010 | Todaro M; Iovino F; Eterno V; Cammareri P; Gambara G; Espina V; Gulotta G; Dieli F; Giordano S; De Maria R; Stassi G. | |
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis | 2010 | Cepero V; Sierra JR; Giordano S. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile